Visão geral da empresa
A biopharmaceutical entity headquartered in Australia, Immuron Limited is dedicated to the research, development, and commercialization of polyclonal antibodies across the United States, Canada, and its domestic market. The company operates within the Healthcare sector, specifically under the Biotechnology industry, where it focuses on developing therapeutic solutions such as Travelan for specific medical applications. The firm maintains a lean operational structure with a total employee count of 7 individuals, which reflects a highly specialized and resource-constrained organization typical of early-stage biotech ventures. With a market capitalization of $8.17M and trailing twelve-month revenue of $7.48M, the company operates at a micro-cap scale, indicating a niche market position rather than broad commercial dominance. These valuation and revenue figures suggest that the enterprise is in a growth or development phase, where current financial outputs are insufficient to fully cover operating expenses, yet the asset base holds potential value based on future product milestones.
Saúde financeira
The company reported a revenue of $7.48M for the trailing twelve months, alongside a net income of $-4,646,242 and an EBITDA of $-4,739,534, highlighting a significant disparity between top-line generation and bottom-line profitability. The substantial gap between the positive revenue of $7.48M and the negative net income reveals a cost structure characterized by high operating expenditures that consume nearly all generated income before reaching the bottom line. Free cash flow stands at $-3,420,940, indicating that the company is currently burning cash to fund its R&D activities and operational needs, which limits immediate financial flexibility for dividends or acquisitions. Gross margin stands at 63.7%, suggesting a high value-added product mix, whereas the operating margin of -47.2% and profit margin of -62.1% demonstrate that fixed costs and research expenses are eroding profitability at a steep rate. The balance sheet shows a cash position of $10.00M against a debt load of $203,914, resulting in a debt-to-equity ratio of 1.56, which presents a mixed picture of liquidity versus leverage. Although the current ratio of 8.04 indicates robust short-term liquidity and the ability to cover obligations, the elevated debt-to-equity ratio suggests a reliance on equity financing to manage liabilities. Return on Equity is recorded at -39.7% and Return on Assets at -21.9%, metrics that reveal management is currently generating negative returns on the capital invested in the company. These negative return metrics are typical for biotechnology firms in the development stage but signal that the business model has not yet achieved positive leverage on its equity base.
Avaliação de valorização
The trailing twelve-month P/E ratio is listed as N/A due to the lack of positive net income, while the forward P/E is reported at -80.00, implying that the market anticipates earnings to remain negative in the near term based on current projections. The price-to-book ratio of 0.71 indicates that the stock trades at a discount to its book value, suggesting the market prices the company conservatively relative to its tangible assets. The price-to-sales ratio of 1.09 and the EV/EBITDA of -53.07 provide alternative valuation perspectives, showing that the market values the company based on revenue generation rather than profitability, which is common for pre-revenue or loss-making biotech firms. The 52-week high was $2.39 and the 52-week low was $0.68, meaning the current trading price sits significantly below the annual peak but above the recent trough. The beta value of 0.36 indicates that the stock exhibits low volatility relative to the broader market, moving less than half as much as the overall index in typical market conditions. This low beta suggests the stock may serve as a defensive position within a portfolio, though the negative P/E metrics warn of the inherent risks associated with the company's current profitability status.
Growth & Income
Revenue growth year-over-year stands at 4.8%, while earnings growth is listed as N/A due to the company's consistent losses, implying that revenue expansion is the primary driver of company progress rather than profit scaling. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all available earnings are theoretically retained, though currently negative, to fund operations and research rather than being distributed to shareholders. The lack of a dividend payout ratio renders the traditional measure of sustainability irrelevant, as the company reinvests its limited cash flow and external capital into product development instead of generating shareholder yield through distributions. Overall, the growth and income profile is defined by modest revenue expansion without earnings contribution, relying entirely on capital markets and cash reserves to fund future commercialization efforts.